8279.TWO Syngen Biotech Co.,Ltd.
- Market cap
- TWD 2.18B
- P/E
- 10.6x
- P/B
- 0.92x
- ROE
- 9.2%
- Dividend yield
- 6.23%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 8279.TWO undervalued?
Graham number8279.TWO trades 33.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Syngen Biotech Co.,Ltd. fundamental analysis
No fundamental analysis for Syngen Biotech Co.,Ltd. yet.
Syngen Biotech Co.,Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Syngen Biotech Co.,Ltd.
Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, and capsules; and elderly health care, beauty enhancing supplem…
Full company profileSyngen Biotech Co.,Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Syngen Biotech Co.,Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.47B | 1.93B | 1.84B | 2.01B | 2.14B | 2.09B |
| Gross Profit | 528M | 688M | 644M | 724M | 724M | 668M |
| Operating Income | 282M | 380M | 294M | 310M | 324M | 279M |
| EBITDA | - | 488M | 442M | 424M | 462M | 393M |
| Net Income | 238M | 321M | 275M | 240M | 272M | 222M |
| EPS | 8.77 | 12 | 10 | 8.86 | 10 | 8.21 |
| Balance Sheet | ||||||
| Total Assets | 2.42B | 3.07B | 3.11B | 3.08B | 3.05B | 3.14B |
| Total Liabilities | 644M | 1.08B | 975M | 849M | 675M | 736M |
| Shareholders' Equity | 1.77B | 1.99B | 2.13B | 2.24B | 2.37B | 2.40B |
| Cash & Short-term Investments | 315M | 246M | 367M | 342M | 275M | 322M |
| Cash Flow | ||||||
| Operating Cash Flow | 336M | 277M | 415M | 348M | 319M | 327M |
| Capital Expenditure | 61.7M | 585M | 93.8M | 64.3M | 76.4M | 78.2M |
| Free Cash Flow | 275M | -307M | 321M | 284M | 243M | 249M |
| Ratios | ||||||
| ROE | 13.4% | 16.1% | 12.9% | 10.7% | 11.4% | 9.2% |
| ROA | 9.8% | 10.5% | 8.8% | 7.8% | 8.9% | 7.1% |
| Net Profit Margin | 16.2% | 16.6% | 15.0% | 11.9% | 12.7% | 10.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Syngen Biotech Co.,Ltd. dividends
- Dividend yield
- 6.23%
- Forward dividend
- 5.00 TWD
- Payout ratio
- 49.9%
- Ex-dividend date
- Jun 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 136M | 5.00 | 49.9% |
| 2024 | TWD 136M | 5.00 | 56.4% |
| 2023 | TWD 136M | 5.00 | 49.3% |
| 2022 | TWD 108M | 4.00 | 33.7% |
| 2021 | TWD 94.9M | 3.50 | 39.9% |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1100:1000 on Jul 9, 2018.
Who owns Syngen Biotech Co.,Ltd.
- Insiders 63.54%
- Institutions 4.62%
- Public & others 31.83%
- Shares outstanding 27.1M
- Free float 11.0M
Syngen Biotech Co.,Ltd. company profile
- Company name
- Syngen Biotech Co.,Ltd.
- Ticker
- 8279.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Building A, Tainan City, Taiwan, 73055
- Phone
- 886 6 505 8168
- Website
- syngen.com.tw
About Syngen Biotech Co.,Ltd.
Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, and capsules; and elderly health care, beauty enhancing supplements, probiotics, digestive aids and enzymes, weight loss and nutrition, immune acid, fitness and energy, and pet supplement products. It also provides science-based and bio active pharmaceutical ingredients, including Oraltics, a lactobacillus fermentum SG-A95; IMMUPHYLA, a heat-killed lactobacillus paracasei LCW23; V3, a lactobacillus fermentum; ST4SanTex, a streptococcus thermophilus; GUARDSPO, a bacillus coagulans; benefiGANO, a ganoderma lucidum, EXPUNERGY, a hirsutella sinensis mycelium; and BIOJOVIAL, a lactobacillus brevis. In addition, the company offers organic food OEM/ODM, explosion proof extraction, brand agency, and wholesale distribution services. It serves sport nutrition, beauty enhancement, baby and mother care, weight management, and digestion and detox industries. Syngen Biotech Co.,Ltd. was founded in 1988 and is based in Tainan City, Taiwan.
Syngen Biotech Co.,Ltd. management
3- Wei Ren ChenChairman of the Board and President
- Zhi Ming HuangFinance Manager
- Zihui WangAccounting Supervisor